Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation -- Ignore unavailable to you. Want to Upgrade?

To: 9wald9 who wrote (424)	1/12/2005 9:18:56 AM
From: 9wald9	Read Replies (1) \| Respond to of 557

More bullish news re TGEN: Sirna (RNAI) has chosen to advance its HD program by using the TGEN AAV dilivery program. "We are excited to continue expanding our AAV-based gene delivery platform into the area of RNA interference by working with Sirna, the leading company developing this innovative technology," said H. Stewart Parker, President and Chief Executive Officer of Targeted Genetics. "This collaboration is consistent with our strategy to leverage our gene delivery capabilities beyond gene replacement. Shutting down the production of disease-causing proteins by delivering expressed RNAi sequences complements the other applications of our technologies: providing a functional copy of the gene deficient in cystic fibrosis, delivering a gene encoding a therapeutic protein for rheumatoid arthritis and stimulating the immune system using a DNA-based vaccine against HIV."